- Evelo Biosciences Inc EVLO has announced data from its Phase 2 study of EDP1815 for mild and moderate psoriasis.
- A statistically significant reduction in the Psoriasis Area and Severity Index (PASI) score from baseline at week 16 was observed in the study.
- 25% to 32% of patients across the three cohorts treated with EDP1815 achieved a PASI-50 (50% change from baseline) at week 16 compared to 12% on placebo.
- In cohorts 1 and 2 the difference in response rate was statistically significant.
- Though cohort 3 was directionally similar (25% vs. 12%).
- The pooled PASI-50 response across all three EDP1815 cohorts, an exploratory analysis, was 29% vs. 12% for placebo and was also statistically significant with a p-value of 0.027.
- An increase in the number of capsules of EDP1815 did not lead to dose-response.
- EDP1815 was observed to be well tolerated in the Phase 2 study.
- Adverse events (AEs) classified as "gastrointestinal" were comparable between active and placebo groups, with no meaningful differences in diarrhea, abdominal pain, nausea, or vomiting rates.
- Price Action: EVLO stock is up 6.90% at $7.75 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in